FLORIDA BOARD OF PHARMACY
ONCOLOGY PHARMACIST CERTIFICATION
EXAM WITH ACTUAL QUESTIONS AND
VERIFIED ANSWERS, PLUS EXPLAINED
RATIONALES/EXPERT VERIFIED FOR
GUARANTEED 100% PASS 2026/LATEST
UPDATE/INSTANT DOWNLOAD PDF
1. A 62-year-old patient with diffuse large B-cell lymphoma is
scheduled to receive R-CHOP. Which component of the regimen is
most directly associated with a risk of cardiomyopathy, making
baseline and cumulative cardiac assessment particularly important?
A. Rituximab
B. Cyclophosphamide
C. Doxorubicin
D. Vincristine
Answer: C. Doxorubicin
Rationale: Doxorubicin is an anthracycline whose cumulative
exposure is associated with dose-dependent cardiotoxicity and
potentially irreversible cardiomyopathy. Baseline cardiac function,
commonly assessed with left ventricular ejection fraction when
clinically appropriate, and cumulative anthracycline exposure should
be considered. Rituximab can cause infusion reactions,
cyclophosphamide can cause myelosuppression and hemorrhagic
cystitis, and vincristine is particularly associated with peripheral and
autonomic neuropathy.
1
,2. A patient receiving high-dose methotrexate develops delayed
clearance. Which intervention is most appropriate when severe
methotrexate toxicity is developing despite aggressive hydration and
leucovorin rescue?
A. Administer folic acid only
B. Administer glucarpidase when criteria for toxic delayed elimination
are met
C. Administer filgrastim immediately
D. Administer mesna
Answer: B. Administer glucarpidase when criteria for toxic delayed
elimination are met
Rationale: Glucarpidase enzymatically hydrolyzes methotrexate into
inactive metabolites and can rapidly reduce systemic methotrexate
concentrations in patients with toxic concentrations and delayed
elimination, particularly in the setting of renal dysfunction.
Leucovorin rescue remains essential and should not simply be
discontinued. Mesna prevents ifosfamide/cyclophosphamide
urotoxicity and filgrastim addresses neutropenia rather than
methotrexate accumulation.
3. A patient receiving cisplatin develops worsening serum creatinine
and hypomagnesemia. Which toxicity profile best explains this
laboratory pattern?
A. Nephrotoxicity and electrolyte wasting
B. Hemorrhagic cystitis
C. Severe cardiomyopathy
D. Immune-mediated hepatitis
Answer: A. Nephrotoxicity and electrolyte wasting
2
,Rationale: Cisplatin is strongly associated with cumulative
nephrotoxicity and renal magnesium wasting. Patients may also
experience nausea and vomiting, peripheral neuropathy, and
ototoxicity. Adequate hydration and appropriate electrolyte monitoring
are central components of cisplatin administration. Mesna is not
routinely used to prevent cisplatin nephrotoxicity.
4. A patient receiving irinotecan develops severe diarrhea shortly
after infusion. Which pharmacologic intervention is most
appropriate for acute cholinergic diarrhea occurring during or
shortly after administration?
A. Atropine
B. Loperamide
C. Octreotide
D. Diphenhydramine
Answer: A. Atropine
Rationale: Irinotecan can produce an acute cholinergic syndrome
characterized by abdominal cramping, diaphoresis, salivation,
lacrimation, and early-onset diarrhea. Atropine is commonly used to
treat or prevent this acute cholinergic reaction when clinically
appropriate. Delayed irinotecan diarrhea, which occurs later, is
generally managed with aggressive antidiarrheal therapy such as
loperamide according to the clinical situation.
5. A patient with metastatic colorectal cancer is receiving
fluorouracil. Which toxicity is particularly characteristic of
fluoropyrimidine therapy?
A. Severe hemorrhagic cystitis
B. Mucositis and diarrhea
3
, C. Permanent alopecia in every patient
D. Ototoxicity
Answer: B. Mucositis and diarrhea
Rationale: Fluorouracil can cause significant gastrointestinal toxicity,
including mucositis and diarrhea, as well as myelosuppression and
hand-foot syndrome depending on exposure and administration
schedule. Severe or unexpected fluoropyrimidine toxicity should
prompt consideration of dihydropyrimidine dehydrogenase deficiency
because impaired metabolism can cause profound toxicity.
6. A patient develops profound, unexpectedly severe toxicity shortly
after initiation of fluorouracil. Which pharmacogenomic issue
should the oncology pharmacist consider?
A. TPMT deficiency
B. DPYD deficiency
C. UGT1A1 ultrarapid metabolism
D. CYP2D6 ultrarapid metabolism
Answer: B. DPYD deficiency
Rationale: Dihydropyrimidine dehydrogenase, encoded by DPYD, is
responsible for the major catabolic pathway of fluoropyrimidines.
Clinically significant DPD deficiency can markedly increase exposure
and produce severe or potentially fatal toxicity. Pharmacogenomic
evaluation and appropriate dose modification or avoidance may be
warranted according to the patient's genotype/phenotype and
applicable guidance. TPMT is principally relevant to thiopurines,
while UGT1A1 is particularly relevant to irinotecan.
4
ONCOLOGY PHARMACIST CERTIFICATION
EXAM WITH ACTUAL QUESTIONS AND
VERIFIED ANSWERS, PLUS EXPLAINED
RATIONALES/EXPERT VERIFIED FOR
GUARANTEED 100% PASS 2026/LATEST
UPDATE/INSTANT DOWNLOAD PDF
1. A 62-year-old patient with diffuse large B-cell lymphoma is
scheduled to receive R-CHOP. Which component of the regimen is
most directly associated with a risk of cardiomyopathy, making
baseline and cumulative cardiac assessment particularly important?
A. Rituximab
B. Cyclophosphamide
C. Doxorubicin
D. Vincristine
Answer: C. Doxorubicin
Rationale: Doxorubicin is an anthracycline whose cumulative
exposure is associated with dose-dependent cardiotoxicity and
potentially irreversible cardiomyopathy. Baseline cardiac function,
commonly assessed with left ventricular ejection fraction when
clinically appropriate, and cumulative anthracycline exposure should
be considered. Rituximab can cause infusion reactions,
cyclophosphamide can cause myelosuppression and hemorrhagic
cystitis, and vincristine is particularly associated with peripheral and
autonomic neuropathy.
1
,2. A patient receiving high-dose methotrexate develops delayed
clearance. Which intervention is most appropriate when severe
methotrexate toxicity is developing despite aggressive hydration and
leucovorin rescue?
A. Administer folic acid only
B. Administer glucarpidase when criteria for toxic delayed elimination
are met
C. Administer filgrastim immediately
D. Administer mesna
Answer: B. Administer glucarpidase when criteria for toxic delayed
elimination are met
Rationale: Glucarpidase enzymatically hydrolyzes methotrexate into
inactive metabolites and can rapidly reduce systemic methotrexate
concentrations in patients with toxic concentrations and delayed
elimination, particularly in the setting of renal dysfunction.
Leucovorin rescue remains essential and should not simply be
discontinued. Mesna prevents ifosfamide/cyclophosphamide
urotoxicity and filgrastim addresses neutropenia rather than
methotrexate accumulation.
3. A patient receiving cisplatin develops worsening serum creatinine
and hypomagnesemia. Which toxicity profile best explains this
laboratory pattern?
A. Nephrotoxicity and electrolyte wasting
B. Hemorrhagic cystitis
C. Severe cardiomyopathy
D. Immune-mediated hepatitis
Answer: A. Nephrotoxicity and electrolyte wasting
2
,Rationale: Cisplatin is strongly associated with cumulative
nephrotoxicity and renal magnesium wasting. Patients may also
experience nausea and vomiting, peripheral neuropathy, and
ototoxicity. Adequate hydration and appropriate electrolyte monitoring
are central components of cisplatin administration. Mesna is not
routinely used to prevent cisplatin nephrotoxicity.
4. A patient receiving irinotecan develops severe diarrhea shortly
after infusion. Which pharmacologic intervention is most
appropriate for acute cholinergic diarrhea occurring during or
shortly after administration?
A. Atropine
B. Loperamide
C. Octreotide
D. Diphenhydramine
Answer: A. Atropine
Rationale: Irinotecan can produce an acute cholinergic syndrome
characterized by abdominal cramping, diaphoresis, salivation,
lacrimation, and early-onset diarrhea. Atropine is commonly used to
treat or prevent this acute cholinergic reaction when clinically
appropriate. Delayed irinotecan diarrhea, which occurs later, is
generally managed with aggressive antidiarrheal therapy such as
loperamide according to the clinical situation.
5. A patient with metastatic colorectal cancer is receiving
fluorouracil. Which toxicity is particularly characteristic of
fluoropyrimidine therapy?
A. Severe hemorrhagic cystitis
B. Mucositis and diarrhea
3
, C. Permanent alopecia in every patient
D. Ototoxicity
Answer: B. Mucositis and diarrhea
Rationale: Fluorouracil can cause significant gastrointestinal toxicity,
including mucositis and diarrhea, as well as myelosuppression and
hand-foot syndrome depending on exposure and administration
schedule. Severe or unexpected fluoropyrimidine toxicity should
prompt consideration of dihydropyrimidine dehydrogenase deficiency
because impaired metabolism can cause profound toxicity.
6. A patient develops profound, unexpectedly severe toxicity shortly
after initiation of fluorouracil. Which pharmacogenomic issue
should the oncology pharmacist consider?
A. TPMT deficiency
B. DPYD deficiency
C. UGT1A1 ultrarapid metabolism
D. CYP2D6 ultrarapid metabolism
Answer: B. DPYD deficiency
Rationale: Dihydropyrimidine dehydrogenase, encoded by DPYD, is
responsible for the major catabolic pathway of fluoropyrimidines.
Clinically significant DPD deficiency can markedly increase exposure
and produce severe or potentially fatal toxicity. Pharmacogenomic
evaluation and appropriate dose modification or avoidance may be
warranted according to the patient's genotype/phenotype and
applicable guidance. TPMT is principally relevant to thiopurines,
while UGT1A1 is particularly relevant to irinotecan.
4
